Protara Therapeutics
Update in progressTARA (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on transformative therapies for cancer and rare diseases. Its lead program, TARA-002, is an investigational cell therapy in Phase II for non-muscle invasive bladder cancer and lymphatic malformations. The company is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients on parenteral nutrition and fluids. Headquartered in New York, NY.
Company score
- Sentiment
- 0.25
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Jesse Shefferman
- Employees46
- Websitewww.protaratx.com
Identifiers
- ISINUS74365U1079
- FIGIBBG001ZLYSH5
- LEI549300VWUGH3220TG273
- CUSIP04300J107
- CIK0001359931